Haipry: SDIC Securities Co., Ltd.\'s temporary fiduciary management affairs report on the pre-loss of the 2023 annual performance of Shenzhen Haipuri Pharmaceutical Group Co., Ltd.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.